Protagonist Therapeutics (NASDAQ: PTGX) reported Q4 EPS of $0.44, $0.58 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $60 million versus the consensus estimate of $40 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.